CoChat
Cited by 45

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aeruginosa Infections

Blomquist, Kathleen C., Nix, David E. · 2021 · Annals of Pharmacotherapy

Abstract

Objective: This article critically evaluates common Pseudomonas aeruginosa resistance mechanisms and the properties newer β-lactam antimicrobials possess to evade these mechanisms. Data Sources: An extensive PubMed, Google Scholar, and ClinicalTrials.gov search was conducted (January 1995 to July 2020) to identify relevant literature on epidemiology, resistance mechanisms, antipseudomonal agents, newer β-lactam agents, and clinical data available pertaining to P aeruginosa. Study Selection and Data Extraction: Relevant published articles and package inserts were reviewed for inclusion. Data Synthesis: Therapeutic options to treat P aeruginosa infections are limited because of its intrinsic and acquired resistance mechanisms. The goal was to identify advances with newer β-lactams and characterize improvements in therapeutic potential for P aeruginosa infections. Relevance to Patient Care and Clinical Practice: Multidrug-resistant (MDR) P aeruginosa isolates are increasingly encountered from a variety of infections. This review highlights potential activity gains of newer β-lactam antibacterial drugs and the current clinical data to support their use. Pharmacists will be asked to recommend or evaluate the use of these agents and need to be aware of information specific to P aeruginosa, which differs from experience derived from Enterobacterales infections. Conclusions: Newer agents, including ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relebactam, and cefiderocol, are useful for the treatment of MDR P aeruginosa infections. These agents offer improved efficacy and less toxicity compared with aminoglycosides and polymyxins and can be used for pathogens that are resistant to first-line antipseudomonal β-lactams. Selection of one agent over another should consider availability, turnaround of susceptibility testing, and product cost. Efficacy data specific for pseudomonal infections are limited, and there are no direct comparisons between the newer agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1060028020974003

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 66

  1. 10.2165/00003495-200767030-00003 · DOI · Paper page
  2. 10.1128/CMR.00040-09 · DOI · Paper page
  3. 10.1128/AAC.01587-18 · DOI
  4. 10.1002/14651858.CD003344.pub3 · DOI · Paper page
  5. 10.1128/JCM.02072-18 · DOI
  6. 10.1128/JCM.00203-19 · DOI · Paper page
  7. 10.3390/antibiotics9040189 · DOI
  8. 10.1592/phco.27.11.1490 · DOI
  9. 10.1093/cid/ciz1159 · doi:10.1093/cid/ciz1159
  10. 10.1128/AAC.00296-11 · DOI · Paper page
  11. 10.1007/s10123-018-0030-1 · doi:10.1007/s10123-018-0030-1
  12. 10.1128/AAC.03098-15 · DOI · Paper page
  13. 10.1021/ar300327a · DOI
  14. 10.1093/femsre/fux020 · DOI · Paper page
  15. 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
  16. 10.1111/j.1348-0421.1995.tb02193.x · DOI
  17. Naenna P, 2010, Southeast Asian J Trop Med Public Health, 41, 614
  18. 10.1016/j.ijmm.2011.10.001 · DOI · Paper page
  19. 10.1016/j.bjid.2016.10.008 · DOI
  20. 10.1128/aac.44.12.3322-3327.2000 · DOI · Paper page
  21. 10.1007/s10156-002-0193-7 · DOI
  22. 10.1099/jmm.0.001106 · DOI
  23. 10.3855/jidc.9486 · doi:10.3855/jidc.9486
  24. 10.1128/AAC.03057-14 · DOI · Paper page
  25. 10.1128/AAC.03681-14. · DOI
  26. 10.1128/AAC.03681-14 · DOI
  27. 10.1128/AAC.06064-11 · DOI
  28. 10.1128/AAC.04238-14 · DOI
  29. 10.1016/j.ijantimicag.2018.07.027 · doi:10.1016/j.ijantimicag.2018.07.027
  30. 10.1093/jac/dky204 · DOI
  31. 10.1093/ofid/ofz522 · DOI
  32. 10.1007/s40265-013-0168-2 · DOI · Paper page
  33. 10.1371/journal.pone.0180121 · doi:10.1371/journal.pone.0180121
  34. 10.1128/AAC.01737-10 · DOI
  35. 10.1128/AAC.01590-12 · DOI
  36. 10.1128/AAC.02462-13 · DOI · Paper page
  37. 10.1016/j.jgar.2020.04.017 · DOI
  38. 10.1093/ofid/ofy280 · DOI
  39. 10.1128/AAC.02291-19 · DOI
  40. 10.1093/cid/ciz816 · DOI · Paper page
  41. 10.1128/AAC.03074-15 · doi:10.1128/aac.03074-15
  42. 10.1016/S1473-3099(19)30403-7 · DOI · Paper page
  43. 10.1016/S0140-6736(14)62220-0 · DOI · Paper page
  44. 10.1128/AAC.01443-17 · DOI · Paper page
  45. 10.1001/jama.2018.0438 · DOI · Paper page
  46. 10.1007/s40121-018-0214-1 · DOI · Paper page
  47. 10.1128/AAC.00513-10 · DOI
  48. 10.1128/AAC.00513-10 · DOI
  49. 10.1128/AAC.00843-15 · DOI
  50. 10.1007/s40121-018-0214-1 · DOI · Paper page
  51. 10.1128/AAC.00633-16 · DOI · Paper page
  52. 10.1002/phar.2378 · DOI
  53. 10.1128/AAC.00830-15 · DOI · Paper page
  54. 10.1007/s40265-017-0851-9 · DOI · Paper page
  55. 10.2217/fmb-2018-0054 · DOI
  56. 10.1093/cid/ciaa381 · DOI
  57. 10.1016/j.diagmicrobio.2019.05.001 · DOI
  58. 10.1093/jac/dkx139 · DOI · Paper page
  59. 10.1093/cid/ciz530 · DOI · Paper page
  60. 10.1111/nyas.12024 · DOI
  61. 10.1128/AAC.02531-16 · DOI
  62. 10.1016/j.ijantimicag.2018.11.007 · DOI
  63. 10.1128/AAC.01454-17 · DOI · Paper page
  64. 10.1016/S1473-3099(18)30554-1 · DOI · Paper page
  65. 10.2147/IDR.S225553 · DOI
  66. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Dulin D, Clancy CJ. Infectious Disease Society of America antimicrobial resistant treatment guidance: gram-negative bacterial infections. A focus on extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenemresistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR- P aeruginosa ). Accessed October 17, 2020. https://www.idsociety.org/globalassets/idsa/practice-guidelines/amr-guidance/idsa-amr-guidance.pdf · DOI · Paper page

Cited by

See all 45

Metadata

Authors
Blomquist, K. C., & Nix, D. E.
Affiliations
Department of Pharmacy Practice & Science, University of Arizona, Tucson, Arizona, USA
Venue
Annals of Pharmacotherapy
Published
2020-11-23
Volume
55
Issue
8
Pages
1010-1024
ISSN
  • 1060-0280
  • 1542-6270
Cited by
45
References
2
Language
en
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aeruginosa Infections. https://app.cochat.ai/papers/10.1177/1060028020974003
The paper
Blomquist, K. C., & Nix, D. E. (2021). A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aeruginosa Infections. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028020974003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.